CHADDS FORD, Pa., Jan. 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM(R)( )(lidocaine topical patch 5%).
The Paragraph IV certification notice refers to U.S. Patent No. 5,827,529, which covers the formulation of LIDODERM, a topical patch to relieve the pain of postherpetic neuralgia launched in 1999. This patent is listed in the U.S. Food and Drug Administration’s (FDA) Orange Book and expires in October 2015.
About Endo
Safe Harbor Statement
Endo Pharmaceuticals
